A clinical trial listing update for cerebrolysin was recorded on August 11, 2026. The study, titled "Cerebrolysin After Reperfusion in Extended-window Endovascular Thrombectomy," is registered under identifier NCT06339411. It is designated as a Phase 2 trial. According to the listing, the trial status is currently "not yet recruiting," meaning participant enrollment has not yet begun as of this update.
No outcome data, efficacy findings, or safety results have been posted for this trial at this stage. The listing reflects only the trial's registration status, phase designation, and title as provided in the public record. Cerebrolysin remains classified as an unapproved compound in the research context described here, and this update does not represent any regulatory approval or clinical endorsement.
Readers interested in the study can review the full registration details, including eligibility criteria and planned design, through the official clinical trials database entry once further information becomes available. As with any trial in the "not yet recruiting" stage, timelines for enrollment, completion, and results reporting may change.
For more background on this compound, readers can consult the compound overview page.